Patent EP0682256A1 successfully refreshed from Google Patents.
EP0682256A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Methods of detecting collagen degradation in vivo
Assignee: Washington Research Foundation
•
Filing: 1990-11-30
•
Granted: —
•
Expires: 2010-11-30
Abstract
Abstract The invention provides a method of determining type II or type III collagen degradation, comprising quantitating in a body fluid, optionally urine, blood, serum or synovial fluid, the concentration of at least a first 3-hydroxypyridinium cross-linked type II or type III collagen telopeptide.
Inventors
- 👤 David R. Eyre
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-02 13:12
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/68; G01N33/6881; C; C07; C07K; C07K14/00; C07K14/435; C07K14/78; C07K16/00; C07K16/18; C07K7/00; C07K7/02; G01N33/6887; G01N2333/00; G01N2333/435; G01N2333/46; G01N2333/47; G01N2333/4701; G01N2333/4712; G01N2333/78; G01N2800/00; G01N2800/10; G01N2800/101; G01N2800/102; G01N2800/105; G01N2800/108
Claims Analysis
Total Claims: 27
Claim 1
Independent Claim
40 words
A method of determining type II or type III collagen degradation, comprising quantitating in a body fluid, optionally urine, blood, serum or synovial fluid, the concentration of at least a first 3-hydroxypyridinium cross-linked type II or type III collagen telopeptide.
Claim 2
Dependent Claim
44 words
A method of claim 1 further comprising the step of quantitating in a body fluid the concentration of a second 3-hydroxypyridinium cross-linked type II or type III collagen telopeptide, wherein the 3-hydroxypyridinium cross-link of one of the collagen telopeptides has a cleaved pyridinium ring.
Claim 3
Dependent Claim
26 words
A method of claim 2, which method comprises contacting the body fluid with at least one specific binding partner to the first and/or the second polypeptide.
Claim 4
Independent Claim
60 words
A method of determining cartilage degradation in vivo, comprising quantitating in a body fluid the concentrations of a first peptide comprising a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link which has an intact pyridinium ring, and a second peptide comprising a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link which has a cleaved pyridinium ring.
Claim 5
Independent Claim
56 words
A method of any one of claims 2 to 4, wherein the first and second peptides have the structure: wherein is hydroxylysyl pyridinoline, said first and second peptides containing an intact or a cleaved pyridinium ring, respectively; or wherein is hydroxylysyl pyridinoline, said first and second peptides containing an intact or a cleaved pyridinium ring, respectively.
Claim 6
Independent Claim
52 words
A method of determining collagenous connective tissue degradation in vivo, comprising quantitating in a body fluid the concentrations of a first peptide comprising a type III collagen telopeptide containing a 3-hydroxy-pyridinium cross-link, and a second peptide comprising a type III collagen telopeptide containing a 3-hydroxypyridinium cross-link which has a cleaved pyridinium ring.
Claim 7
Dependent Claim
12 words
A method of claim 6, wherein the 3-hydroxypyridinium cross-link is hydroxylysyl pyridinoline.
Claim 8
Independent Claim
37 words
A method of any one of claims 2, 3, 6 or 7 wherein the type III collagen telopeptide is: wherein is hydroxylysyl pyridinoline, said first and second peptides containing an intact or a cleaved pyridinium ring, respectively.
Claim 9
Independent Claim
21 words
A method of any one of claims 2 to 8, wherein the body fluid is urine, blood, serum, or synovial fluid.
Claim 10
Dependent Claim
31 words
A kit for carrying out a method of any one of claims 1 to 9, comprising at least one specific binding partner to said type II or type III collagen telopeptide.
Claim 11
Independent Claim
40 words
A method of determining cartilage degradation in vivo, comprising quantitating the concentration of a peptide in a body fluid, optionally urine, blood, serum, or synovial fluid, said peptide comprising a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link.
Claim 12
Dependent Claim
26 words
A method of claim 11, wherein the detecting step comprises contacting the body fluid with a specific binding partner to said C-terminal type II collagen telopeptide.
Claim 13
Dependent Claim
25 words
A method of claim 11 or claim 12, wherein the C-terminal type II collagen telopeptide is: wherein is hydroxylysyl pyridinoline or wherein is hydroxylysyl pyridinoline
Claim 14
Independent Claim
48 words
A method of determining collagenous connective tissue degradation in vivo, comprising quantitating the concentration of a peptide in a body fluid, optionally urine, blood, serum, or synovial fluid, said peptide comprising a type III collagen telopeptide containing a 3-hydroxy-pyridinium cross-link, optionally wherein the 3-hydroxypyridinium cross-link is hydroxylysyl pyridinoline.
Claim 15
Dependent Claim
26 words
A method of claim 14, wherein the detecting step comprises contacting the body fluid with a specific binding partner to said type III collagen cross-linked telopeptide.
Claim 16
Dependent Claim
19 words
A method of claim 14 or claim 15, wherein the type III collagen telopeptide is: wherein is hydroxylysyl pyridinoline
Claim 17
Dependent Claim
92 words
A peptide comprising an amino acid sequence of a C-terminal type II collagen telopeptide containing a 3-hydroxypyridinium cross-link, the peptide having an amino acid composition of 2 Asx, 2 Glx, 9 Gly, 7 Pro, 5 Leu, 3 Arg, 1 His, 1 Val, and 1 hydroxylysyl pyridinoline residue, wherein each Asx is independently selected form the group consisting of Asp and Asn, and each Glx is independently selected from the group consisting of Glu and Gln, or the peptide has an amino acid composition given above less from 1 to 21 amino acids.
Claim 18
Dependent Claim
19 words
A peptide of claim 17, having the amino acid sequence wherein is hydroxylysyl pyridinoline or wherein is hydroxylysyl pyridinoline
Claim 19
Dependent Claim
120 words
A peptide comprising an amino acid sequence of a type III collagen telopeptide and having a 3-hydroxypyridinium cross-link, the peptide having an amino acid composition of 2 Glx, 4 Tyr, 4 Ser, 2 Asx, 4 Val, 5 Gly, 2 Ala, 1 Ile, 1 His, 1 Arg, and one hydroxylysyl pyridinoline residue, or 13 Gly, 2 Ile, 2 Glx, 4 Ala, 3 Phe, 1 Pro, 1 Met, 1 His, 1 Arg, and one hydroxylysyl pyridinoline residue, wherein each Asx is independently selected from the group consisting of Asp and Asn, and each Glx is independently selected from the group consisting of Glu and Gln, or the peptide has an amino acid composition given above less from 1 to 18 amino acids.
Claim 20
Dependent Claim
14 words
A peptide of claim 19, having the amino acid sequence wherein is hydroxylysyl pyridinoline
Claim 21
Dependent Claim
48 words
A test kit for carrying out a method of any one of claims 1 to 9 or 11 to 16, comprising a specific binding partner to a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or to a type III collagen telopeptide containing a 3-hydroxypyridinoline cross-link.
Claim 22
Dependent Claim
37 words
A test kit comprising one or more immunological binding partners that specifically bind to a C-terminal type II collagen telopeptide containing a hydroxylysyl pyridinoline cross-link or to a type III collagen telopeptide containing a hydroxylysyl pyridinoline cross-link.
Claim 23
Independent Claim
87 words
A method of analyzing body fluids for the presence of an analyte indicative of a physiological condition, comprising the steps of contacting the body fluid with a specific binding partner for said analyte, and detecting any binding that occurs between the analyte and the specific binding partner, the improvement comprising contacting the body fluid with at least one specific binding partner to a cross-linked telopeptide having a sequence identical to that of a cross-linked telopeptide produced in vivo upon degradation of type II or type III collagen.
Claim 24
Dependent Claim
21 words
A cell line that produces a monoclonal antibody that binds to a peptide of any one of claims 17 to 20.
Claim 25
Dependent Claim
10 words
An antibody obtainable from a cell line of claim 24.
Claim 26
Dependent Claim
15 words
An antibody that binds to a peptide of any one of claims 17 to 20.
Claim 27
Dependent Claim
53 words
The use of a specific binding partner for one or more of a 3-hydroxypyridinium cross-linked type II or type III collagen telopeptide or a derivative of such a telopeptide having a 3-hydroxypyridinium cross-link with a cleaved pyridinium ring, in the preparation of an agent for investigating type II or type III collagen degradation.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.